DE69841058D1 - Behandlung von hämatologischen störungen - Google Patents
Behandlung von hämatologischen störungenInfo
- Publication number
- DE69841058D1 DE69841058D1 DE69841058T DE69841058T DE69841058D1 DE 69841058 D1 DE69841058 D1 DE 69841058D1 DE 69841058 T DE69841058 T DE 69841058T DE 69841058 T DE69841058 T DE 69841058T DE 69841058 D1 DE69841058 D1 DE 69841058D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- hematological disorder
- neoplastic
- gvhd
- hematologic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000014951 hematologic disease Diseases 0.000 title abstract 2
- 208000024908 graft versus host disease Diseases 0.000 abstract 2
- 230000001613 neoplastic effect Effects 0.000 abstract 2
- 208000019838 Blood disease Diseases 0.000 abstract 1
- 206010068051 Chimerism Diseases 0.000 abstract 1
- 230000000735 allogeneic effect Effects 0.000 abstract 1
- 230000003750 conditioning effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 230000001400 myeloablative effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cereal-Derived Products (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7323097P | 1997-11-14 | 1997-11-14 | |
PCT/US1998/024209 WO1999025367A2 (en) | 1997-11-14 | 1998-11-13 | Treatment of hematologic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69841058D1 true DE69841058D1 (de) | 2009-09-24 |
Family
ID=22112521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69841058T Expired - Lifetime DE69841058D1 (de) | 1997-11-14 | 1998-11-13 | Behandlung von hämatologischen störungen |
Country Status (8)
Country | Link |
---|---|
US (3) | US6558662B2 (de) |
EP (1) | EP1030675B1 (de) |
JP (1) | JP2001523645A (de) |
AT (1) | ATE439137T1 (de) |
AU (1) | AU1585799A (de) |
CA (1) | CA2309919A1 (de) |
DE (1) | DE69841058D1 (de) |
WO (1) | WO1999025367A2 (de) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001523645A (ja) * | 1997-11-14 | 2001-11-27 | ザ・ゼネラル・ホスピタル・コーポレイション | 血液学的疾患の処置 |
WO2000045842A2 (en) | 1999-02-04 | 2000-08-10 | The General Hospital Corporation | Methods for human allografting |
DE10050334A1 (de) * | 2000-10-11 | 2002-04-25 | Gsf Forschungszentrum Umwelt | Verwendung von Stammzellen und CD6-depletierten Stammzellen zur Toleranzinduktion gegenüber allogenen Transplantaten und/oder zur Leukämiebehandlung |
CA2428721A1 (en) * | 2000-11-14 | 2002-05-23 | The General Hospital Corporation | Blockade of t cell migration into epithelial gvhd target tissues |
US20030031652A1 (en) * | 2001-04-16 | 2003-02-13 | Bernhard Hering | Systems and methods for inducing mixed chimerism |
AU2002309703A1 (en) * | 2001-05-09 | 2002-11-18 | The University Of Louisville Research Foundation, Inc. | Hematopoietic stem cell chimerism to treat autoimmune disease |
US20030147859A1 (en) * | 2001-06-18 | 2003-08-07 | Yair Reisner | Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological tolerance |
US20030032631A1 (en) * | 2001-08-13 | 2003-02-13 | Mcdonald George B. | Method of treatment of cancer by controlling graft-versus-leukemia using topical active corticosteriods |
CA2486621A1 (en) * | 2002-05-22 | 2003-12-04 | The Cleveland Clinic Foundation | Induction and maintenance of tolerance to composite tissue allografts |
US20050058641A1 (en) * | 2002-05-22 | 2005-03-17 | Siemionow Maria Z. | Tolerance induction and maintenance in hematopoietic stem cell allografts |
US20040071666A1 (en) * | 2002-05-24 | 2004-04-15 | The Regents Of The University Of Michigan | Compositions and methods related to graft-versus-host disease |
US20050058622A1 (en) * | 2002-12-06 | 2005-03-17 | Lyman Stewart D. | Methods of using Flt3-Ligand in hematopoietic cell transplantation procedures incorporating nonmyeloablative conditioning regimens |
EP1601248A4 (de) * | 2003-02-13 | 2010-01-27 | Anthrogenesis Corp | Verwendung von nabelschnurblut zur behandlung von subjekten, die an einer krankheit, einem leiden oder einer störung leiden |
JP2004256444A (ja) * | 2003-02-26 | 2004-09-16 | Kansai Tlo Kk | 悪性腫瘍の治療方法 |
US7435592B2 (en) | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
WO2005021734A2 (en) * | 2003-09-02 | 2005-03-10 | University Of Massachussets | Generation of hematopoietic chimerism and induction of central tolerance |
WO2005030999A1 (en) * | 2003-09-25 | 2005-04-07 | Dana-Farber Cancer Institute, Inc | Methods to detect lineage-specific cells |
WO2005042019A1 (en) * | 2003-10-22 | 2005-05-12 | University Of Rochester | Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis |
KR101544292B1 (ko) | 2004-10-25 | 2015-08-12 | 셀러랜트 세라퓨틱스 인코퍼레이티드 | 골수형 세포군의 증량 방법 및 그의 용도 |
JP2007087270A (ja) * | 2005-09-26 | 2007-04-05 | Tsukuba Brains Kk | 再生医療支援システム |
AU2006320162B2 (en) * | 2005-12-02 | 2013-07-25 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
US20070179810A1 (en) * | 2006-01-05 | 2007-08-02 | Goodman Edward L | Controls for antimicrobial use and infection |
CN101421393B (zh) * | 2006-02-14 | 2013-08-14 | 塞勒兰特治疗公司 | 提高造血干细胞植入的方法和组合物 |
WO2008034071A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Method of identifying patients suitable for high-dose cyclophosphamide treatment |
WO2008034074A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
WO2008128299A1 (en) * | 2007-04-24 | 2008-10-30 | Murdoch Childrens Research Institute | Therapeutic protocol for treating hemoglobinopathy |
WO2009067699A2 (en) * | 2007-11-21 | 2009-05-28 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for an oxazaphosphorine drug regimen |
US9026372B2 (en) * | 2007-11-21 | 2015-05-05 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen |
KR101604649B1 (ko) * | 2007-11-27 | 2016-03-18 | 베리덱스, 엘엘씨 | 혈액 내 순환 흑색종 세포의 자동화된 계산 및 특징화 |
WO2010011879A2 (en) * | 2008-07-25 | 2010-01-28 | The Johns Hopkins University | Methods and compositions for treating and preventing autoimmune diseases |
JP5997257B2 (ja) | 2011-04-20 | 2016-09-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 単一サイクルでコンディショニングおよび化学選択を組み合わせる方法 |
US9682106B2 (en) | 2011-04-20 | 2017-06-20 | The Regents Of The University Of California | Method for combined conditioning and chemoselection in a single cycle |
DK2793914T3 (da) * | 2011-12-22 | 2021-04-26 | Yeda Res & Dev | Kombinationsterapi til en stabil og langvarig transplantation |
CA2868465C (en) * | 2012-04-20 | 2022-12-13 | Angimmune, Llc | Immunomodulation by anti-cd3 immunotoxins to treat cancers bearing surface cd3 |
US9504717B2 (en) | 2013-02-26 | 2016-11-29 | The Board Of Trustees Of The Leland Stanford Junior University | Combined organ and hematopoietic cells for transplantation tolerance of HLA mismatched grafts |
EP3386543B1 (de) | 2015-11-10 | 2021-07-21 | City of Hope | Konditionierungsschemata und verfahren zur induzierung von gemischtem chimärismus |
CA3070258A1 (en) | 2017-07-18 | 2019-01-24 | Calimmune, Inc. | A modulatable switch for selection of donor modified cells |
US20200368363A1 (en) * | 2017-11-29 | 2020-11-26 | Magenta Theerapeutics, Inc. | Compositions and methods for the depletion of cd2+ cells |
EP3765044A4 (de) | 2018-03-12 | 2021-12-08 | Medeor Therapeutics, Inc. | Verfahren zur behandlung von nichtkanzerösen erkrankungen unter verwendung von hämatopoetischen zellen |
US10842821B2 (en) | 2018-04-05 | 2020-11-24 | Medeor Therapeutics, Inc. | Cellular compositions derived from prior organ donors and methods of manufacture and use thereof |
US10881692B2 (en) | 2018-04-05 | 2021-01-05 | Medeor Therapeutics, Inc. | Compositions for establishing mixed chimerism and methods of manufacture thereof |
US11813376B2 (en) | 2018-09-18 | 2023-11-14 | Medeor Therapeutics, Inc. | Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof |
US11435350B2 (en) | 2018-09-18 | 2022-09-06 | Medeor Therapeutics, Inc. | Methods of analysis of blood from deceased donors |
US20210379113A1 (en) * | 2018-10-31 | 2021-12-09 | Magenta Therapeutics Inc. | Methods for hematopoietic stem and progenitor cell transplant therapy |
MX2021012961A (es) | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Res Gmbh | Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos. |
EP3965782A4 (de) * | 2019-05-09 | 2023-03-08 | The General Hospital Corporation | Verfahren zur induktion von hämatopoetischem chimärismus |
US20230165958A1 (en) * | 2020-04-27 | 2023-06-01 | Children's Hospital Medical Center | Precision Dosing Regimen |
WO2022040210A1 (en) * | 2020-08-18 | 2022-02-24 | City Of Hope | Haploidentical mixed chimerism for treating autoimmune diseases |
JP2023549559A (ja) * | 2020-11-18 | 2023-11-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ナチュラルキラー細胞に対する枯渇モノクローナル抗体 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5192553A (en) | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
US5004681B1 (en) | 1987-11-12 | 2000-04-11 | Biocyte Corp | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
ATE215375T1 (de) * | 1992-01-08 | 2002-04-15 | Gen Hospital Corp | Induzierte toleranz gegen transplantate |
US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
WO1994020619A1 (en) | 1993-03-05 | 1994-09-15 | Université Catholique de Louvain | LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T-CELL ACTIVATION AND PROLIFERATION |
US5730979A (en) * | 1993-03-05 | 1998-03-24 | Universite Catholique Delouvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
WO1995003062A1 (en) * | 1993-07-21 | 1995-02-02 | Cellpro, Incorporated | Methods and compositions for preventing immune rejection of solid organ grafts |
US5635156A (en) * | 1993-09-13 | 1997-06-03 | University Of Pittsburgh | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
US5484612A (en) * | 1993-09-22 | 1996-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
US5599703A (en) | 1993-10-28 | 1997-02-04 | The United States Of America As Represented By The Secretary Of The Navy | In vitro amplification/expansion of CD34+ stem and progenitor cells |
EP0752868A1 (de) * | 1994-03-31 | 1997-01-15 | Diacrin, Inc. | Verbesserte verfahren zur transplantation unter verwendung von modifizierten zellen und t-zellinhibierenden agenzien |
WO1996006165A1 (en) | 1994-08-19 | 1996-02-29 | The General Hospital Corporation | Genetically engineered swine cells |
WO1997041863A1 (en) | 1996-05-09 | 1997-11-13 | The General Hospital Corporation | Mixed chimerism and tolerance |
US6544787B1 (en) | 1996-11-15 | 2003-04-08 | Hadash Medical Research Services And Development Ltd. | Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation |
JP2001523645A (ja) * | 1997-11-14 | 2001-11-27 | ザ・ゼネラル・ホスピタル・コーポレイション | 血液学的疾患の処置 |
-
1998
- 1998-11-13 JP JP2000520800A patent/JP2001523645A/ja active Pending
- 1998-11-13 WO PCT/US1998/024209 patent/WO1999025367A2/en active Application Filing
- 1998-11-13 DE DE69841058T patent/DE69841058D1/de not_active Expired - Lifetime
- 1998-11-13 CA CA002309919A patent/CA2309919A1/en not_active Abandoned
- 1998-11-13 AT AT98960199T patent/ATE439137T1/de not_active IP Right Cessation
- 1998-11-13 EP EP98960199A patent/EP1030675B1/de not_active Expired - Lifetime
- 1998-11-13 US US09/191,970 patent/US6558662B2/en not_active Expired - Lifetime
- 1998-11-13 AU AU15857/99A patent/AU1585799A/en not_active Abandoned
-
2003
- 2003-02-25 US US10/374,302 patent/US7408039B2/en not_active Expired - Fee Related
-
2008
- 2008-08-04 US US12/185,427 patent/US7892578B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20010048921A1 (en) | 2001-12-06 |
JP2001523645A (ja) | 2001-11-27 |
WO1999025367A2 (en) | 1999-05-27 |
EP1030675A2 (de) | 2000-08-30 |
EP1030675B1 (de) | 2009-08-12 |
US6558662B2 (en) | 2003-05-06 |
CA2309919A1 (en) | 1999-05-27 |
US7892578B2 (en) | 2011-02-22 |
ATE439137T1 (de) | 2009-08-15 |
US20090028870A1 (en) | 2009-01-29 |
US20030157077A1 (en) | 2003-08-21 |
WO1999025367A3 (en) | 1999-08-05 |
AU1585799A (en) | 1999-06-07 |
US7408039B2 (en) | 2008-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69841058D1 (de) | Behandlung von hämatologischen störungen | |
BG110703A (en) | PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNF ALPHA AND HIS APPLICATION | |
PL328858A1 (en) | Immunogenous peptides | |
ATE326239T1 (de) | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren | |
DE3483040D1 (de) | Maschinelesbares dokument und dessen behandlung. | |
IL189629A0 (en) | Compositions containing human ctla-4 antibodies | |
MY129189A (en) | Prostaglandin agonists and their use to treat bone disorders | |
NO166943C (no) | Analogifremgangsmaate for fremstilling av enzymresistente immunomodulerende peptider. | |
WO2001023405A3 (en) | Therapeutic treatment of androgen receptor driven conditions | |
DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
TR200301846T2 (tr) | Cripto bloke edici Antikorlar ve bu antikorların kullanımları. | |
DE69914726D1 (de) | Zusammensetzung zur regulierung des hauterscheinungsbildes | |
DE69316948D1 (de) | Lösliche Liganden für CD40 | |
MXPA02000119A (es) | Elementos mezcladores estaticos apilados. | |
UA70925C2 (uk) | Спосіб лікування естрогенстимульованого раку | |
ATE362374T1 (de) | Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust | |
ATE222769T1 (de) | Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens | |
ATE311853T1 (de) | Verwendung von krillenzymen zur behandlung von zahnbelag | |
TW200640944A (en) | VGF polypeptides and methods of treating VGF-related disorders | |
GB9009106D0 (en) | Processes and intermediates for synthetic antibody derivatives | |
IL141550A0 (en) | Methods and compositions for the prevention or treatment of cancer | |
ATE220557T1 (de) | Darmprotozoen-impfstoffe | |
MXPA02000680A (es) | Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf. | |
ATE261724T1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen | |
DE69835828D1 (de) | Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |